TY - GEN
T1 - Integrated microfluidic platform for utilizing aptamer-based ELISA-like assay for simultaneous detection of multiple cardiovascular clinical samples
AU - Sinha, Anirban
AU - Gopinathan, Priya
AU - Chung, Yi Da
AU - Shieh, Shu Chu
AU - Lee, Gwo Bin
N1 - Funding Information:
The authors would like to thank the Ministry of Science and Technology in Taiwan (MOST 106-2221-E-007-001 and MOST 107-2221-E-007-013-MY3) for funding this work. Partial financial support from the “Higher Education Support Project” of Taiwan’s Ministry of Education (Grant No.107Q2713E1) is also greatly appreciated.
Funding Information:
The authors would like to thank the Ministry of Science and Technology in Taiwan (MOST 106-2221-E-007-001 and MOST 107-2221-E-007-013-MY3) for funding this work. Partial financial support from the ?Higher Education Support Project? of Taiwan?s Ministry of Education (Grant No.107Q2713E1) is also greatly appreciated.
Publisher Copyright:
Copyright © (2018) by Chemical and Biological Microsystems Society. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Cardiovascular diseases (CVDs) have been documented as one of the leading causes of deaths with an estimated death toll of 17 million. Early detection may reduce the high risk of sudden deaths associated with it. Current biomedical sensing processes vastly rely on antigen-antibody based detection processes, which have limitations in point-of-care applications. In this work, we developed an integrated microfluidic platform for the simultaneous detection up to six clinical samples using a highly specific aptamer for recognizing the protein followed by an antibody-based chemiluminescence assay for the detection of CVDs biomarker, N-terminal pro-b-type natriuretic peptide (NT-proBNP) in less than 30 minutes. A fully automated on-chip detection of NT-proBNP was performed using only 15 µL of clinical samples from each patient. It may serve a promising tool for CVDs monitoring and diagnosis.
AB - Cardiovascular diseases (CVDs) have been documented as one of the leading causes of deaths with an estimated death toll of 17 million. Early detection may reduce the high risk of sudden deaths associated with it. Current biomedical sensing processes vastly rely on antigen-antibody based detection processes, which have limitations in point-of-care applications. In this work, we developed an integrated microfluidic platform for the simultaneous detection up to six clinical samples using a highly specific aptamer for recognizing the protein followed by an antibody-based chemiluminescence assay for the detection of CVDs biomarker, N-terminal pro-b-type natriuretic peptide (NT-proBNP) in less than 30 minutes. A fully automated on-chip detection of NT-proBNP was performed using only 15 µL of clinical samples from each patient. It may serve a promising tool for CVDs monitoring and diagnosis.
UR - http://www.scopus.com/inward/record.url?scp=85079895881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079895881&partnerID=8YFLogxK
M3 - Conference contribution
AN - SCOPUS:85079895881
T3 - 22nd International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2018
SP - 1181
EP - 1184
BT - 22nd International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2018
PB - Chemical and Biological Microsystems Society
T2 - 22nd International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2018
Y2 - 11 November 2018 through 15 November 2018
ER -